Has the Valuation of the "Water Sellers" Bottomed Out?

·

The domestic pharmaceutical and biotechnology sector in China has moved beyond the traditional paradigm of “drugs reign supreme.”

Nearly 29 years ago, Harbin Pharmaceutical Group became the first publicly listed pharmaceutical company in China, marking the beginning of a new era for biotech firms entering the capital markets. Since then, the number of listed pharmaceutical companies has surged, with expanding scale and increasingly diversified sub-sectors. By September 2022, more than half of the top 20 most valuable pharmaceutical and biotech firms were non-drug focused—highlighting a structural shift. Notably, three of these leading companies operate in the Contract Research Organization (CRO) space.

CROs, often dubbed the “water sellers” of innovative drug development, thrived during the biotech bull market from early 2019 to mid-2021. Benefiting from China’s innovation-driven drug discovery boom and rising offshore outsourcing demand from global clients, CROs emerged as one of the most high-growth, high-conviction segments within the healthcare sector.

However, over the past year, CROs have faced steep valuation corrections—leading many investors to ask: Has the CRO sector’s valuation finally reached its bottom?

👉 Discover how market cycles shape high-potential investment opportunities today.

Back to Square One: A Reset in Valuation

After a dramatic rise and subsequent fall, CRO valuations have returned—almost full circle—to levels seen at the start of 2019.

Following a two-and-a-half-year run fueled by structural tailwinds, the broader pharmaceutical sector entered a significant correction phase starting mid-2021. This period marked the most intense market reset in five years, with high valuations being systematically unwound—and CROs were hit particularly hard.

As of September 2022, leading CRO companies’ price-to-earnings (P/E) ratios (TTM) had dropped to levels comparable to—or even below—those observed before the 2019 bull market began. This suggests two key developments:

Valuation, after all, reflects market expectations about future growth under prevailing macroeconomic conditions. While these expectations evolve over time, they are not arbitrary—they hinge on fundamental views about industry sustainability and investor sentiment. Understanding both internal dynamics and external market shifts helps clarify whether current valuations truly reflect a bottom.

The Rise and Fall: Two Years Up, One Year Down

The Bull Run: 2019–2021

The surge in CRO valuations between 2019 and 2021 was no accident—it resulted from a powerful convergence of three factors: favorable market conditions, strong operational growth, and rising investor awareness.

1. Supportive Market Environment
The broader healthcare sector enjoyed a structural bull market during this period. Inflows from foreign institutional investors—drawn by long-term yield potential—combined with growing retail participation through thematic funds created strong buying momentum. Even non-healthcare funds began allocating capital to pharmaceuticals due to outperformance.

2. Strong Industry Fundamentals
Domestic CROs, many founded in the 1990s, entered a phase of rapid expansion post-2015. With low base effects and robust order pipelines translating into real revenue growth, CROs delivered impressive results. From 2018 to 2021, the sector’s compound annual growth rate (CAGR) in revenue exceeded 30%. This sustained high growth justified premium valuations.

3. Increasing Market Recognition
Prior to 2018, large-scale publicly traded CROs were rare in China. That changed when WuXi AppTec returned to the A-share market, paving the way for other players to list. By late 2022, over ten CRO firms were publicly traded. This greater visibility elevated the sector’s profile among investors and enhanced its capacity to absorb institutional capital.

During this phase, every positive catalyst—strong quarterly earnings, new contracts, or employee incentive plans—tended to boost sentiment. Investors viewed CROs as a novel, high-growth story with limited downside risk.

The Correction: Mid-2021 Onward

Since mid-2021, however, valuations have sharply declined due to both sector-wide headwinds and growing concerns about CRO-specific risks.

1. Capital Rotation and Macro Pressures
In H2 2021, capital shifted toward booming sectors like renewables and cyclical industries, pulling liquidity away from healthcare. In 2022, rising U.S. interest rate expectations further pressured growth stocks—including CROs—amplifying sell-offs. Regulatory uncertainty added to investor caution, accelerating de-rating.

Today, leading CROs trade at P/E multiples similar to pre-bull market levels—suggesting much of the downside risk may already be priced in.

2. Maturing Investor Sentiment
As understanding of the CRO model deepened, investors began questioning whether growth could continue at previous rates. Concerns mounted around:

These factors fed into a negative feedback loop: falling sentiment led to lower valuations, which in turn discouraged investment and exacerbated volatility.

What’s Changed—and What Hasn’t?

With valuations back at 2019 levels, where might the CRO sector go from here?

1. Market Conditions Are Reaching an Inflection Point

The broader pharmaceutical sector now sits in an unusually weak position across three metrics: low valuations, low institutional ownership, and low trading volume share.

As of late 2022:

Historically, such “triple-low” conditions are rare—and rarely last long. Periods of extreme pessimism have typically preceded rebounds driven by renewed confidence and portfolio rebalancing.

👉 See why savvy investors are watching cyclical rebounds in growth sectors closely.

Thus, it’s unlikely that further broad-based downward pressure will come from overall market sentiment. Instead, as perceptions normalize around healthcare’s long-term growth potential, a recovery in valuations—including for CROs—becomes increasingly plausible.

2. Underlying Growth Drivers Remain Intact

Despite short-term noise, we remain confident in the long-term outlook for CROs.

Global R&D Demand Remains Strong
While private biotech funding dipped in early 2022, it represents only a fraction of total pharmaceutical R&D spending. Moreover, investment activity showed signs of recovery in H2 2022. Meanwhile, Chinese CROs continue benefiting from a competitive edge—leveraging skilled labor at lower costs and proven efficiency in delivering high-quality services. Leading firms report sustained growth in preclinical offshore outsourcing orders.

Domestic Innovation Is Accelerating
China’s aging population and evolving disease burden create urgent demand for novel therapies. Government policies—including faster regulatory approvals and value-based医保 negotiations—are incentivizing innovation. As clinical standards align with global practices, the penetration of R&D outsourcing is expected to rise further.

Even if some CROs show slower order growth compared to peak years, this must be viewed in context: their revenue base is now much larger. Maintaining proportional growth amid scale expansion is itself an achievement.

FAQ: Addressing Key Investor Questions

Q: Why are CROs called 'water sellers'?
A: The term refers to their role in supporting innovators (the "gold miners") by providing essential tools and services without directly developing drugs themselves—much like selling shovels during a gold rush.

Q: Are CRO valuations still expensive?
A: No. After over a year of correction, leading CROs now trade near or below pre-bull market P/E levels—with minimal valuation premium versus global peers.

Q: Is offshore outsourcing still growing?
A: Yes. Despite geopolitical concerns, cost efficiency and proven quality make China a preferred destination for global pharma clients—especially in preclinical research.

Q: How does domestic policy affect CRO growth?
A: Policies promoting innovation—such as fast-track approvals and value-based reimbursement—are actually supportive of R&D activity and increase demand for outsourcing services.

Q: Can CROs grow despite funding downturns in biotech startups?
A: Yes. While early-stage financing impacts some clients, large pharmaceutical companies—which account for most outsourcing spend—maintain stable R&D budgets.

Q: What signals should investors watch for a turnaround?
A: Look for stabilization in order growth rates, rising institutional ownership in healthcare funds, regulatory clarity, and improving sentiment in global biotech capital markets.

In summary, while near-term sentiment remains cautious, the current valuation environment appears to have priced in most bearish scenarios. The core drivers of long-term growth—global R&D demand, domestic innovation momentum, and competitive advantages—are still firmly intact.

👉 Explore how strategic positioning during downturns can unlock outsized returns.

CROs may no longer be the shiny new story they once were—but that doesn’t mean they’ve lost their shine. For forward-looking investors, today’s reset could represent a compelling entry point.

Core Keywords: CRO companies, pharmaceutical innovation, drug development outsourcing, biotech sector valuation, healthcare investment outlook, contract research organization growth, global R&D demand